caa a22 4500 605498253 CHVBK 20210128100545.0 cr unu---uuuuu 210128e20150801xx s 000 0 eng 10.1007/s00253-015-6776-x doi (NATIONALLICENCE)springer-10.1007/s00253-015-6776-x Probiotic Saccharomyces cerevisiae strains as biotherapeutic tools: is there room for improvement? [Elektronische Daten] [Mariana Palma, Daniel Zamith-Miranda, Flaviano Martins, Fernando Bozza, Leonardo Nimrichter, Mônica Montero-Lomeli, Ernesto Marques Jr, Bruno Douradinha] The probiotic yeast Saccharomyces cerevisiae var boulardii is widely used as a low cost and efficient adjuvant against gastrointestinal tract disorders such as inflammatory bowel disease and treatment of several types of diarrhea, both in humans and animals. S. boulardii exerts its protective mechanisms by binding and neutralizing enteric pathogens or their toxins, by reducing inflammation and by inducing the secretion of sIgA. Although several S. cerevisiae strains have proven probiotic potential in both humans and animals, only S. boulardii is currently licensed for use in humans. Recently, some researchers started using S. boulardii as heterologous protein expression systems. Combined with their probiotic activity, the use of these strains as prophylactic and therapeutic proteins carriers might result in a positive combined effort to fight specific diseases. Here, we provide an overview of the current use of S. cerevisiae strains as probiotics and their mechanisms of action. We also discuss their potential to produce molecules with biotherapeutic application and the advantages and hurdles of this approach. Finally, we suggest future directions and alternatives for which the combined effort of specific immunomodulatory effects of probiotic S. cerevisiae strains and ability to express desired foreign genes would find a practical application. Springer-Verlag Berlin Heidelberg, 2015 Probiotics nationallicence Saccharomyces cerevisiae nationallicence Saccharomyces cerevisiae var boulardii nationallicence Mechanisms of action nationallicence Expression of heterologous proteins nationallicence Palma Mariana Laboratório de Dermatologia e Imunodeficiências, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil aut Zamith-Miranda Daniel Instituto de Microbiologia Paulo Goés, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil aut Martins Flaviano Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil aut Bozza Fernando Instituto de Pesquisa Clinica Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil aut Nimrichter Leonardo Instituto de Microbiologia Paulo Goés, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil aut Montero-Lomeli Mônica Instituto de Bioquímica Médica Leopoldo de Meis, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil aut Marques Jr Ernesto University of Pittsburgh Center for Vaccine Research, room 9052, 15213, Pittsburgh, PA, USA aut Douradinha Bruno University of Pittsburgh Center for Vaccine Research, room 9052, 15213, Pittsburgh, PA, USA aut Applied Microbiology and Biotechnology Springer Berlin Heidelberg 99/16(2015-08-01), 6563-6570 0175-7598 99:16<6563 2015 99 253 https://doi.org/10.1007/s00253-015-6776-x text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 review-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s00253-015-6776-x text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Palma Mariana Laboratório de Dermatologia e Imunodeficiências, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil aut NATIONALLICENCE 700 1- Zamith-Miranda Daniel Instituto de Microbiologia Paulo Goés, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil aut NATIONALLICENCE 700 1- Martins Flaviano Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil aut NATIONALLICENCE 700 1- Bozza Fernando Instituto de Pesquisa Clinica Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil aut NATIONALLICENCE 700 1- Nimrichter Leonardo Instituto de Microbiologia Paulo Goés, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil aut NATIONALLICENCE 700 1- Montero-Lomeli Mônica Instituto de Bioquímica Médica Leopoldo de Meis, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil aut NATIONALLICENCE 700 1- Marques Jr Ernesto University of Pittsburgh Center for Vaccine Research, room 9052, 15213, Pittsburgh, PA, USA aut NATIONALLICENCE 700 1- Douradinha Bruno University of Pittsburgh Center for Vaccine Research, room 9052, 15213, Pittsburgh, PA, USA aut NATIONALLICENCE 773 0- Applied Microbiology and Biotechnology Springer Berlin Heidelberg 99/16(2015-08-01), 6563-6570 0175-7598 99:16<6563 2015 99 253